This site is intended for health professionals only

Study finds natalizumab benefit in MS


Natalizumab may be appropriate for some patients as an alternative to cytotoxic therapy for multiple sclerosis (MS), a vignette study has found.

The clinical review of natalizumab used the format of a case vignette followed by discussion of natalizumab as a potential therapy.

The case was of a woman aged 30 diagnosed with MS two years previously. Interferon-beta was not tolerated due to worsening of depression. Despite treatment with glatiramer and high-dose corticosteroid, she had three recent acute attacks and is being considered for natalizumab.

The author briefly discusses the effects and epidemiology of MS, noting its a high impact on quality of life, and cost

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine